Navigation Links
Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Date:8/16/2013

Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports. As many as 96% of men with testicular cancer now survive at least ten years from diagnosis (1), but more advanced forms need to be treated with combination chemotherapy which can have serious long-term complications. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have therefore been searching for new treatments that would reduce the risk of relapse after initial treatment and so spare as many men as possible from needing combination chemotherapy.

The new pilot study, published in the August issue of prestigious journal the Annals of Oncology, tested a new treatment in a pilot study of men with stage IIA and IIB testicular seminoma where the cancer has spread to the lymph nodes in the abdomen.

The researchers showed that giving chemotherapy drug carboplatin before radiotherapy could reduce relapse rates compared with radiotherapy alone cutting the numbers of men who would need follow-up treatment. It also allowed radiation doses to be reduced. The study was funded by The Institute of Cancer Research (ICR), the Bob Champion Cancer Trust and Cancer Research UK, as well as through the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.

Researchers gave 51 men with stage IIA and IIB testicular seminoma a single cycle of carboplatin a low toxicity form of chemotherapy followed three to four weeks later by radiotherapy. Most of the men were aged below 50, over a range of 18-73 years.

Adding carboplatin to patients' treatment plans allowed doctors to give a lower dose of radiation over a smaller area of the body for most of the men in the study. Some 39 of the men in the study had their prescription of radiation reduced from the standard 35 Grays (Gy) of radiat
'/>"/>

Contact: Henry French
henry.french@icr.ac.uk
020-715-35312
Institute of Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Neuroblastoma: Autophagy protects from chemotherapy
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Discovery may help prevent chemotherapy-induced anemia
4. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
5. New way to kill lymphoma without chemotherapy
6. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
7. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
8. New biomarker for common lung cancer predicts responses to chemotherapy
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Harmless human virus may be able to boost the effects of chemotherapy
11. Hot flashes before menopause? It can happen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... cancer cells facing potentially lethal antiestrogen therapy recycle to ... cancer cells have receptors for the hormone estrogen, which ... Patients typically get an antiestrogen such as tamoxifen for ... says Dr. Patricia V. Schoenlein, cancer researcher in the ...
... Madison, WI 1 OCTOBER 2008 Not only ... Houston,s George R. Brown Convention Center, beginning this weekend, ... seven scientific societies, but they are bringing focus to ... Meeting under the theme of "Celebrating the International Year ...
... (NorthShore) and Northwestern University have discovered that fiber optic ... blood levels in the colonic lining (mucosa) in humans, ... cancer. The study appears in the October ... of the American Gastroenterological Association (AGA) Institute. ...
Cached Biology News:Breast cancer cells recycle to escape death by hormonal therapy 2Breast cancer cells recycle to escape death by hormonal therapy 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
(Date:5/4/2015)... May 04, 2015 Marianjoy ... patients with arm and hand impairments by acquiring ... its Oakbrook Terrace network site. , Secured through ... is a highly-regarded treatment option for patients with ... Armeo®Spring, Marianjoy becomes one of just four Illinois ...
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... A new report by  visiongain  forecasts the ... in 2019. That revenue forecast and others appear in  ... ,  published in March 2015. ... and qualitative analyses of the antithrombotic drugs market. Visiongain ... London, UK . It produces analyses to ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... SCOTTSDALE, Ariz., Aug. 22 Regenesis Biomedical, ... Wound Therapy,System, announced today the addition of two ... directors are Peter G. Savas, Chairman and CEO ... principal with,Bederson and Company., (Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008 ...
... VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... as,custirsen sodium, received Fast Track designation from the ... docetaxel for progressive,metastatic prostate cancer. OGX-011 is currently ... and breast cancer, and is designed to,inhibit the ...
... TSX Exchange Symbol: RVX, CALGARY, Aug. 21 ... announce that it will host a live,teleconference on ... provide a corporate,update of the Company. Following the ... session., The webcast can be accessed at ...
Cached Biology Technology:Regenesis Biomedical Announces Additions to Board of Directors 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Biology Products: